Studies: Bristol-Myers hepatitis drug bests GSK's

03/8/2006 | AlertNet

The results of two studies of long-term liver disease indicate Bristol-Myers Squibb's entecavir is more effective in treating hepatitis B than GlaxoSmithKline's Epivir. The studies in the New England Journal of Medicine, funded by Bristol-Myers, also said entecavir has a low rate of antiviral resistance.

View Full Article in:

AlertNet

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC